BMY - Bristol-Myers S Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-0.89%) NVAX (1.83%) LAKE (4.97%) AGRX (8.77%) AAPL (-0.29%) BAC (-1.7%) PTON (1.47%) LEDS (0%) APT (17.88%) AMRN (-2.61%) AAOI (-1.9%) JPM (-2.49%) JNJ (-0.15%) JEF (-1.09%) IWM (-1.23%) INTC (8.14%) HOME (-0.5%) HEXO (-6%) HAL (-2.04%) GPRO (0.46%) FDX (-0.53%) FB (-0.83%) ENDP (-10.24%) ELOX (-5.55%) DIS (-1.5%)

Next Earnings Date : 2/6/2020

BMY - Bristol-Myers Squibb...

$64.16 -2.71[-4.06%]

15 mins delayed data

People also watch : LLY | AZN | JNJ | SNY | ABBV | PFE

+Watchlist

5 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$66.87	Open	$66.39
Volume	22.45M	Market Cap	156.755B
Yield	2.45 %	Last Dividend	$1.64

Day

52 Week

Bristol-Myers Squibb: The Merger Is Comp...	01/23/20
Bristol-Myers Squibb has finally completed the acquisition of Celgene, now is the time to shine. The company performed incredibly well in 2019 - bette...

The Daily Biotech Pulse: Roche Reports P...	01/23/20
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) ...

9 Takeaways From The JPMorgan Healthcare...	01/17/20
The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to m...

Is Bristol-Myers Squibb (BMY) a Good Sto...	01/17/20
Is Bristol-Myers Squibb (BMY) a great pick from the value investor's perspective right now? Read on to know more.

15 of the Best Dividend Stocks to Buy fo...	01/15/20
Each offers the potential for capital appreciation and yields that 10-year Treasurys can't provide. Pharmaceutical giant Bristol-Myers Squibb, fresh o...

Bristol-Myers Squibb CEO on the drug pip...	01/13/20
Bristol-Myers Squibb CEO Dr. Giovanni Caforio sits down with CNBC's Jim Cramer at the J.P. Morgan Healthcare Conference in San Francisco, Calif., to d...

Global Cancer Biologics Market 2019-2023...	01/13/20
LONDON--(BUSINESS WIRE)-- #Biotechnology--The global cancer biologics market is poised to grow by USD 40.38 billion during 2019-2023, progressing at a...

Bristol-Myers Squibb's Stock Could Soar ...	01/10/20
Let's review the charts???.TEVA

The Daily Biotech Pulse: Positive Data R...	01/10/20
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) A...

Nektar Therapeutics and Bristol-Myers Sq...	01/10/20
Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab)

ANALYST RATINGS

7 analyst ratings (Last 6 months)

42.86 %

Strong Buy + Buy

Price Target (PT)

Buy rating	01/06/20
and announces Price Target of $73.00

Buy rating	12/13/19
Argus Research upgrades from Hold to Buy rating and announces Price Target of $80.00

Hold rating	11/22/19
and announces Price Target of $60.00

Hold rating	10/23/19
UBS maintains Neutral rating and raises Price Target from $51.00 to $53.00

Buy rating	10/17/19
and announces Price Target of $60.00

Hold rating	10/10/19
and raises Price Target from $49.00 to $50.00

Hold rating	09/03/19
Bank of America maintains Neutral rating and raises Price Target from $46.00 to $49.00

EARNINGS

Date	2019-10-31 (BMO)	Est. (EPS/Rev.)	$1.07/ 5.9B
Actual (EPS/Rev.)	$1.17/ $6.01 B	EPS (TTM)	3.48

TRADERS TRACKING $BMY

Service Name	Trader	% Success
Option Superstars	James Catzen	76.00 %	Subscribe
Alpha Swing Trades	Jonathan	69.00 %	Follow
Options Eagle	George	64.00 %	Follow
Options Marc	Marc M	55.00 %	Follow
Best Trading Ideas	Best Trading Ideas	53.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.